Sandler Alan B. 4

What Happened

• Alan B. Sandler, a director of ALX Oncology Holdings, Inc. (ALXO), received a derivative grant/award covering 10,100 shares on 2026-01-20. The filing reports an acquisition price of $0.00 and a total reported value of $0. This is a grant (compensation/award), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-01-20; Form 4 filed 2026-01-21 (filed the next day — timely).
• Reported terms: 10,100 shares, price $0.00, total $0; transaction code A (award/grant/other acquisition, derivative).
• Vesting: Shares subject to the option vest in 12 equal monthly installments beginning February 20, 2026 (per footnote).
• Shares owned after transaction: Not specified in the provided filing details.
• No 10b5-1, tax-withholding, or sale information reported; this is an award, not an immediate sale or cashless exercise.

Context

• This was a derivative award (option/award with a vesting schedule), so Sandler does not immediately receive freely tradable shares — they vest over time. Awards like this are typically compensation-related and do not directly signal a buy or sell of existing shares.